BAX 326 (Recombinant Factor IX): A Phase 2/3 Prospective, Uncontrolled, Multicenter Study Evaluating Pharmacokinetics, Efficacy, Safety, and Immunogenicity in Previously Treated Pediatric Patients With Severe (FIX Level < 1%) or Moderately Severe (FIX Level 1-2%) Hemophilia B

Trial Profile

BAX 326 (Recombinant Factor IX): A Phase 2/3 Prospective, Uncontrolled, Multicenter Study Evaluating Pharmacokinetics, Efficacy, Safety, and Immunogenicity in Previously Treated Pediatric Patients With Severe (FIX Level < 1%) or Moderately Severe (FIX Level 1-2%) Hemophilia B

Completed
Phase of Trial: Phase II/III

Latest Information Update: 18 Oct 2017

At a glance

  • Drugs Nonacog alfa (Primary)
  • Indications Haemophilia B
  • Focus Adverse reactions; Registrational
  • Sponsors Baxter International; Shire
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 15 Sep 2014 The US FDA has approved nonacog alfa for use in children with haemophilia B based on results from this trial.
    • 11 Dec 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top